Related Experiment Video
Updated: May 29, 2026
Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
[Application of activated eptacog alfa in cardiac surgery]
Maciej Zagórski1, Aleksander Goch
110 Wojskowy Szpital Kliniczny w Bydgoszczy, Klinika Kardiologii i Kardiochirurgii, Kliniczny Oddzial Kardiochirurgii. maciejzag@poczta.fm
Unlabelled:
Severe bleeding in cardiac surgery is often difficult to treatment. Antybleeding drugs often are out of order. The aim of the study was to assess the efficacy of activated eptacog alfa treatment of patients with massive postoperative bleeding, which can not be controlled with conventional therapy
Material And Methods:
Activated eptacog alfa was used in 18 patients after cardiac surgery. The patients had normal results of coagulation screening prior to surgery. We evaluated the average blood loss prior to and after administration of activated eptacog alfa. The average dose was 30.95 mcg/kg following administration of drugs antybleeding, transfusion KKCz, FFP, cryoprecipitate, PLT was decided to include the treatment of activated eptacog alfa.
Results:
At a dose of 30.95 mcg/kg, bleeding stopped in 12 patients. 6 patients required reoperation because of persistent bleeding.
Conclusions:
Administration of activated eptacog alfa clearly limits the amount of transfused blood products. Activated eptacog alfa improves outcomes in patients with intractable postoperative bleeding cardiac surgery. Stops bleeding in patients who received preoperative clopidogrel. 1 patient required reoperation after administration of activated eptacog alfa.
